Copyright
©The Author(s) 2025.
World J Gastroenterol. Oct 7, 2025; 31(37): 110797
Published online Oct 7, 2025. doi: 10.3748/wjg.v31.i37.110797
Published online Oct 7, 2025. doi: 10.3748/wjg.v31.i37.110797
Table 1 General characteristics of the study population and according to the presence of metabolic dysfunction-associated fatty liver disease, n (%)/median (interquartile range)
Variable | Total (n = 331) | MAFLD (n = 97) | Non-MAFLD (n = 234) | P value |
Age (years) (mean ± SD) | 44.99 ± 10.69 | 48.02 ± 10.22 | 43.73 ± 10.64 | < 0.001 |
Age | < 0.001 | |||
Male | 164 (49.55) | 73 (75.26) | 91 (38.89) | |
Female | 167 (50.45) | 24 (24.74) | 143 (61.11) | |
BMI (kg/m2) | 23.1 (21.3-25.3) | 25.4 (23.7-26.8) | 22.4 (20.7-23.8) | < 0.001 |
Underweight | 8 (2.42) | 0 (0) | 8 (3.42) | |
Normal | 151 (45.62) | 14 (14.43) | 137 (58.55) | |
Overweight/obese | 172 (51.96) | 83 (85.57) | 89 (38.03) | |
WC (cm) | 81 (75-88) | 88 (85-93) | 78.5 (74-84) | < 0.001 |
Abdominal obesity | 116 (35.05) | 56 (57.73) | 60 (25.64) | |
SP (mmHg) | 109 (100-120.7) | 117 (109-130) | 105 (98-115) | < 0.001 |
DP (mmHg) | 72 (66-79) | 78 (72-85) | 69 (64-77) | < 0.001 |
TC (mg/dL) | 208 (183-233) | 212 (184-247) | 205 (183-230) | 0.112 |
LDL-c (mg/dL) | 138 (116-166) | 139 (116-165) | 138 (116-166) | 0.851 |
TG (mg/dL) | 113 (82-182) | 180 (133-258) | 95 (74-138) | < 0.001 |
HDL-c (mg/dL) | 47 (41-58) | 41 (37-45) | 51 (44-61) | < 0.001 |
FPG (mg/dL) | 92 (86-99) | 98 (93-105) | 90 (84-96) | < 0.001 |
HbA1C (%) | 5.5 (5.3-5.7) | 5.7 (5.5-5.9) | 5.4 (5.2-5.6) | < 0.001 |
AST (U/L) | 19 (16-23) | 22 (18-26) | 19 (16-22) | < 0.001 |
ALT (U/L) | 20 (15-30) | 26 (20-47) | 18 (13-24) | < 0.001 |
GGT (U/L) | 30 (18-57) | 55 (31-80) | 25 (16-39) | < 0.001 |
White blood cell count (G/L) | 6.19 (5.28-7.33) | 6.61 (5.56-7.71) | 6.07 (5.12-7.07) | 0.001 |
Red blood cell count (T/L) | 4.92 (4.52-5.27) | 5.10 (4.77-5.37) | 4.83 (4.46-5.17) | < 0.001 |
Platelet (G/L) | 259 (225-304) | 265 (220-302) | 258 (229-304) | 0.838 |
UA (mg/dL) | 6.2 (5.1-7.3) | 7.2 (6.1-8.5) | 5.7 (4.8-6.8) | < 0.001 |
Creatinine (mg/dL) | 0.73 (0.62-0.88) | 0.81 (0.69-0.96) | 0.69 (0.61-0.83) | < 0.001 |
Hypertension | 26 (7.85) | 19 (19.59) | 7 (2.99) | < 0.001 |
Dyslipidemia | 305 (92.15) | 96 (98.97) | 209 (89.32) | 0.003 |
Prediabetes/diabetes | 130 (39.27) | 64 (65.98) | 66 (28.21) | < 0.001 |
Hyperuricemia | 136 (41.09) | 63 (64.95) | 73 (31.19) | < 0.001 |
Elevated liver enzymes | 95 (28.70) | 45 (46.39) | 50 (21.37) | < 0.001 |
MS | 71 (21.45) | 53 (54.64) | 18 (7.69) | < 0.001 |
- Citation: Lu NL, Lam HT, Vo TD. Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam. World J Gastroenterol 2025; 31(37): 110797
- URL: https://www.wjgnet.com/1007-9327/full/v31/i37/110797.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i37.110797